Since early 2020, the Pulmonary Fibrosis Foundation has been closely tracking the effects of coronavirus (COVID-19) and its spread across the United States.
COVID-19 has impacted everyone in our community in some manner, and scientists made it a goal to remain up to date on medical and public health advances as our knowledge of the virus's impacts expands.
Pulmonary fibrosis linked to COVID-19
Sean Gallup/Getty Images
COVID-19 individuals with pre-existing interstitial lung disease (ILD) are more vulnerable to severe infection than non-ILD patients, according to several studies, as per News Medical Life Sciences.
Furthermore, individuals with ILD have a considerably greater in-hospital mortality rate than those who do not have ILD.
In a previous international trial, 42.2% of 161 patients with ILD hospitalized with COVID-19 developed idiopathic pulmonary fibrosis, according to in-hospital mortality (IPF).
A similar study conducted in the United States found that patients with ILD are more susceptible to severe COVID-19 than those who do not have ILD.
Another research found that COVID-19 patients with fibrotic ILD had a greater death rate than COVID-19 patients with non-fibrotic ILD.
SARS-CoV-2 infection is 2.4 times more common in patients with ILD than in people who do not have ILD, according to a large population-based investigation.
Due to the lack of a control group in this investigation, scientists were unable to determine the frequency of COVID-19 incidence in the general population.
Nonetheless, they reported that 59.7% of the study cohort had a positive reverse transcriptase-polymerase chain reaction (RT-PCR) result for SARS-CoV-2.
COVID-19-positive IPF patients are more prone to developing a serious infection and requiring oxygen treatment, intensive care, and endotracheal intubation, according to previous research.
Although it is unclear why SARS-CoV-2 infection is linked to a poor prognosis in IPF patients, experts believe it is mostly due to a reduction in pulmonary reserve.
Patients who have had a lung transplant should continue to exercise extreme care.
Wearing a mask, social isolation, and frequent hand washing are all strategies that have been shown to prevent the transmission of COVID-19.
According to recent research by John Hopkins University, lung transplant recipients may have a weaker immune response to the COVID-19 vaccine.
Even though transplant patients had a lower antibody response to the first dosage of COVID-19 mRNA vaccines, the trial is still ongoing, and more information on the second dose-response will be released soon.
The Pulmonary Fibrosis Foundation highly supports COVID-19 immunization, as the benefits significantly exceed the dangers, as recommended by the Centers for Disease Control and Prevention.
The FDA has authorized three vaccinations for Emergency Use Authorization.
There are very few medical reasons to avoid vaccination, so if you're concerned, go to your health care doctor and pulmonologist for further information.
People who are eligible for the COVID-19 vaccine should get the entire dose, including booster shots because the presently approved vaccinations are very successful at lowering disease severity and transmission.
Post-transplant recipients should receive a third dose and a booster vaccination, although they may not be as protected as the general population.
As a result, transplant patients and those who live with them should stay attentive following immunization and continue to take steps to avoid COVID-19 infection.
The US Food and Drug Administration (FDA) has granted Evusheld, AstraZeneca's long-acting monoclonal antibody treatment, emergency use authorization to assist prevent certain immunocompromised persons, including transplant recipients, from COVID-19 infection.
Evusheld is used to prevent COVID-19 infection prior to exposure.
